Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Biomedica Licenses RNAi Tech from Carnegie Institute, UMMS

NEW YORK (GenomeWeb News) - Gene therapy company Oxford Biomedica said today that it has licensed the rights for RNA interference technology from the University of Massachusetts Medical School and the Carnegie Institute of Washington. 
 
Under the agreement, Oxford Biomedica receives non-exclusive rights under the Carnegie and UMSS licensing programs for the RNAi technology and exclusive rights for the technology’s gene therapy applications using lentiviral vectors.
 
Oxford Biomedica’s therapeutic vaccine and gene-based therapy programs are focused on oncology and neurotherapy.
 
Oxford Biomedica will provide an upfront payment, annual maintenance fees, milestone payments, and royalties on sales, the company said.
 
Further financial terms of the agreement were not released.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.